(as at April 1, 2012)

1. Pharmaceuticals

   Code Nonproprietary name	Status (Japan)	Indication
   		Remarks
   JR-401S Somatropin (rDNA origin)	Filed	Short stature associated with small for gestational age
   		Supplementary indication of Growject®
   JR-041 Follicle stimulating hormone (rDNA origin)	Phase II/III in preparation	Infertility
   		Manufactured using JCR's platform serum-free culture technology Out-licensed to ASKA Pharmaceuticals
   JR-032 Iduronate-2-sulfatase (rDNA origin)	Global clinical trials in preparation	Hunter syndrome (lysosomal storage disease)
   		Enzyme replacement therapy Manufactured using JCR's platform serum-free culture technology Co-developed with GlaxoSmithKline Group
   JR-051 Alpha-galactosidase A (rDNA origin)	Global clinical trials in preparation	Fabry disease (lysosomal storage disease)
   		Enzyme replacement therapy Manufactured using JCR's platform serum-free culture technology Co-developed with GlaxoSmithKline Group
   JR-101 Glucocerebrosidase (rDNA origin)	Preclinical	Gaucher disease (lysosomal storage disease)
   		Enzyme replacement therapy Manufactured using JCR's platform serum-free culture technology Co-developed with GlaxoSmithKline Group

2. Cellular Therapy

   Code Nonproprietary name	Status (Japan)	Indication
   		Remarks
   JR-031 Human mesenchymal stem cells	Phase II/III	Graft-versus host disease associated with hematopoietic stem cell transplantation
   		Allogeneic human mesenchymal stem cells Licensed in from Osiris Therapeutics (USA)